Introduction
Primary immune thrombocytopenia (ITP) is an autoimmune heterogeneous disorder presenting with decreased platelet count and increased bleeding risk. Both impaired platelet production and increased platelet destruction are significant in the pathogenesis of ITP, in which autoreactive T cells and innate immune system play important roles [1, 2] .
CD4
+ CD25 hi Foxp3 + Treg cells and CD3 + CD4 + IL-17-producing Th17 cells are two subsets of CD4 + T helper (Th) cells [2] . TGF-and IL-10 producing Treg cells are crucial immune response regulators in autoimmune diseases [3] . It is known that decreased number and dysfunction of Treg cells play important role in ITP [4] . IL-17 produced by Th17 cells lead to subsequent inflammation factors release and tissue damage in ITP and other autoimmune disease [5, 6] . Th17/Treg balance is regarded as a key factor in 2 BioMed Research International immune homeostasis; a variety of autoimmune diseases were caused when Th17/Treg balance is skewed [7] [8] [9] . The ratio of Th17/Treg cells in active SLE patients is significantly higher than that in inactive patients and healthy controls, which associate with the severity of disease [10] . Our previous study indicated that the percentage of Treg cells in ITP patients was significantly lower than that of healthy controls, and the ratio of Th17/Treg correlated with the disease activity of ITP [11] .
The transcription factor interferon regulatory factor (IRF4) has been known to be associated with immune regulation and is essential to the differentiation of the effector CD4 + T helper cell subsets [12] [13] [14] [15] [16] [17] . The previous study in mouse found that the upregulation of IRF4 is dependent on the expression of Foxp3 [18] . In patients with autoimmune diseases, abnormality of Foxp3 expression resulted in IRF4-deficiency, which caused incapable of starting the transcription of downstream gene and impaired immunosuppressive function of Treg cells [18] . IRF4 is a critical transcription factor both for Treg and Th17 cells in CD4 + T cells [19] .
Interleukin-10 (IL-10) is an important regulatory cytokine of Tregs in inflammatory conditions [20] . IL-10 elevates Tregs' suppression against Teffs, while Tregs of ITP patients could not effectively produce enough IL-10 to sufficiently inhibit Teffs [21, 22] . Effective corticosteroids treatment improved the IL-10 production of Tregs in ITP patients, which suggested that IL-10 levels might associate with ITP disease states. IL-10-producing Tregs directly inhibit Th17 and IFN-+ IL-17 + double-producing T cells (IFN-+ IL-17 + Th cells) via IL-10 secretion [23] [24] [25] [26] [27] . Recent studies showed that the increase of IL-10-producing Foxp3
+ Tregs was accompanied with disease remission in several different systematic autoimmune diseases, such as experimental autoimmune encephalomyelitis, diabetes, and arthritis [28] [29] [30] .
Via metabolic reprogramming, CD4 + effector T cells and Treg cells support their proliferation and immunological function [31] . Induced Treg cells have been shown to utilize mainly a distinct metabolic program based on mitochondrial oxidation of lipid and pyruvate [32] [33] [34] . CD4 + CD25 − Teff cells are dependent on aerobic glycolysis for proliferation and inflammatory functions [35, 36] . Whether there is any correlation between the dysfunction of Treg cells and the cell metabolism status remains to be explored.
One the other hand, previous study has shown the impaired ability of IL-10 secretion of Treg cells, which suggests the impairment of Treg cells regulatory function in ITP patients [22] . IL-10 is IRF4-dependent downstream cytokine of Treg cells [18, 37] . It is unclear if there are any associations between the IRF4 with the Th17/Treg imbalances and abnormal secretion of IL-10 in ITP patients, or how the cell metabolism involved in the disease progression is. In the current study, we aimed to investigate the expressions of IL-10 and the immunosuppressive function of Treg regulated by IRF4 and the impact on the balance of Th17/Treg in newly diagnosed ITP patients, in order to better understand the pathogenesis of ITP, and could pave ways to specific immune therapy targeting ITP and other autoimmune diseases. Thirty-six patients with  newly diagnosed ITP were enrolled into this study (20  females and 16 males, age range 19-77 years, and median  age 49 years) (Supplementary Table 2 ). ITP was diagnosed per criteria proposed by an international working group [1, 38, 39] . Twenty healthy volunteers were recruited as normal controls (normal control group, NC group) (Supplementary Table 3 6 PBMCs were adjusted concentration as 5 × 10 5 /ml in RPMI1640 medium supplemented with 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine, 200 U/ml penicillin, and 100 g/ml streptomycin and cultured in 24-well plates overnight. Before stimulation, the supernatants were collected for IL-17 ELISA test. The concentration of PBMCs were stimulated with 50 ng/ml phorbol myristate acetate (PMA, SigmaAldrich, St. Louis, Missouri, USA, Cat# P8139) and 500 ng/ml ionomycin (Sigma-Aldrich, Cat# I9657) for 4 hours. End in 2 hours after incubation, 1 ul/ml brefeldin A solution (BFA, Biolegend, Cat# 420602) was added to the culture system. Then PBMCs were stained with CD4 FITC and CD25 PE-CY7. After the fixation and permeabilization step described above, the cells were stained with IL-17A PerCP-Cy5.5 (BD Bioscience, Cat# 560799). All steps are according to the manufacturer's protocol (Supplementary 4). Acquisition was performed on a FACS Aria II flow cytometer (BD biosciences, USA) and then analyzed using Flowjo software version 7.6.1 (Tritar Inc., San Carlos, California, USA). . . . ELISA. Supernatants from peripheral venous blood samples of patients and volunteers and the cell cultures were collected and stored at -80 ∘ C until the cytokine measurements. The secretions of IL-17A (R&D Systems, Inc., Cat# D1700) by coculture systems and IL-10 (R&D Systems, Inc., Cat# EL217B) by Tregs were measured in duplicate by ELISA following the manufacturer's recommendation. Results were expressed for each subject as cytokine concentration in pictogram per milliliter.
Materials and Methods

. . Patients and Healthy Controls.
. . . Western Blotting. 1 x SDS buffer (Cell Signaling Technology, Cat# 7722) was added to sorting CD4 + CD25 hi Foxp3 + Treg cells from PBMCs. After cracking, samples were ultrasonically processed for 10 to 15 seconds. 20 l sample aliquots were then heated at 95 ∘ C for 5 minutes, and cooled on ice. After centrifuged for 5 minutes, sample aliquots were added on SDS-page gel (Cell Signaling Technology) and combined with biotin labeled protein molecular weight standard (Cell Signaling Technology, Cat# 7727) 10 l per lane. After electrophoresis of protein power transferred to nitrocellulose membrane (Cell Signaling Technology, Cat# 12369), nitrocellulose membrane was cleaned twice at room temperature by 25 ml TBS for 5 minutes each time, incubated in 25 ml sealing fluid at room temperature for 1 hour, and cleaned with 15 ml TBS/T 3 times for 5 minutes each time.
After incubated primary antibodies, anti-IRF4 Ab (Cell Signaling Technology, Cat# 4964s) and -actin (Cell Signaling Technology) were added. The protein bands were detected with an ECL Detection System (Santa Cruz Biotechnology. SignalFire6 ECL Reagent, Cell Signaling Technology, Cat# 6883).
. . . Real-Time PCR. Total RNA was isolated from Treg cells and reverse-transcribed to cDNA using an iSCRIPT cDNA synthesis kit (Bio-Rad). Real-Time PCR (qRT-PCR) was performed using an Applied Biosystems ABI 7500. The primers were purchased from Applied Biosystems and the primer sequences listed in Supplementary Table 1 . Each sample was analyzed in triplicate. Relative gene expression was expressed upon normalization against 18S RNA.
. . . Chromatin Immunoprecipitation (ChIP). CD4
+ CD25 + Treg cells and CD4 + CD25 − Teffs were separated from PBMCs of ITP patients and healthy volunteers with magnetic bead and transferred to the centrifuge. Formaldehyde (270 l, 37%) was added and their final concentration was adjusted 1% for 10 min incubation at room temperature. Then 125 mM icecold glycine (505 ul 2.5 M) was added for another 5 min at room temperature. Cells were washed and supernatant was removed. Protease inhibitors were added to lysis buffer 1 and lysis buffer 2. Pellets were resuspended in 1mL lysis buffer 1 and swirled after 10 min at 4 ∘ C, then centrifuged and abandoned the supernatant. The pellets were resuspended in 300 L of lysis buffer 2 and placed on the ice for 30 min. Then the pellets sonicated on the ice with a Bioruptor. The generated fragments were approximately 500 bp long, as determined experimentally by Agileng 2100 software. 750 l IP buffer, 100 l 5% BSA, magnetic beads-antibody complex, and 4 g anti-IRF4 Ab (Cell Signaling Technology, Cat# 4964s) 30 l were added; 0.6 l Salmon Sperm DNA, 100 l fragments of chromosome, 10 l protease inhibitors, and PMSF 10 l were mixed well. After incubation at 4 ∘ C overnight, the beads were subsequently washed with buffers A, B, and C (according to the instructions), at 4 ∘ C with permanent rotation for 10 mins. Following two washes with TE buffer, samples were eluted in 150 l Chip Elution Buffer for 1 hour at 65 ∘ C. Samples were then added 8 l proteinase K and 6 l NaCI (5 M) and crosslinks reversed at 65 ∘ C overnight. DNA was purified using QIAquick PCR Purification Kit (QIAGEN).
. . . Metabolic Assays of Treg and Teff
Cells. Two hundred mL of Seahorse Bioscience calibrant (pH 7.4) was added to each well of a Seahorse Bioscience 96-well utility plate before the day of assay. The XF96 cell culture plate (Seahorse Bioscience) was coated with 10 L of Cell-Tak (BD Biosciences) which were prepared a working solution in sterile H 2 O. NaHCO 3 0.1 M (pH 8.0) 40 L was added to per well to neutralize and promote adsorption of Cell-Tak to the plate, incubated overnight at 37 ∘ C. Oligomycin, FCCP, and 2-DG (Sigma) were diluted and added as Agilent Seahorse XFe96 Extracellular Flux Assay Kit. OCR and ECAR were measured by XF96 extracellular flux analyzer (Seahorse Bioscience) as described [40] . OCR and ECAR values were normalized to cell number. Glycolytic capacity is distinguished by the difference between the ECAR following the injection of oligomycin and ECAR following glucose injection.
. . . Statistical Analysis. All analyses were performed using SPSS software (version 13.0; SPSS Inc., Chicago, IL, USA). Data are expressed as the mean ± SD. Normality was assessed by Shapiro-Wilk test. Student t test and Wilcoxon rank-sum (Mann-Whitney) test were used for data fulfilled normal distribution and for those did not, respectively. One-way analysis of variance or Kruskal Wallis testing was used for normal or nonnormal data, respectively. The least significant difference test was used for post hoc multiple comparisons. Two-sided p values <0.05 were considered statistically significant.
Results
. 
. . e Target Gene IL-of IRF Was Associated with the Inhibition Function of Treg Cells in ITP Patients.
The expression of IL-10 mRNA, which is IRF4' downstream gene, was measured by ChIP-qPCR (Figures 3(a) and 3(b) Figure 3 
(c). For CD4
+ CD25 − Teffs cells, the intensity of IRF4 binding to IL-10 DNA in patients was lower than that in the normal control group (0.09 ± 0.00 vs 0.27 ± 0.01, p=0.006), Figure 3( had no change compared before and after coculture (H342 13.99 ± 1.572 pg/ml vs 15.49 ± 2.29 pg/ml, p=0.6047; H422 9.13 ± 1.58 pg/ml vs 15.49 ± 2.29 pg/ml, p=0.0516), Figure 4 
. . Abnormal Metabolism of Treg and Teff Cells in ITP
Patients. The role of Tregs and Teffs metabolism was assessed in ITP patients to explore the Tregs and Teffs experience metabolic reprogramming to support proliferation and immunological function [11] . The oxygen consumption rate (OCR) of Treg cells in ITP patients was higher than that of the control group (73.03 ± 11.32 vs 27.97 ± 6.46, p=0.0135), Figure 5 (a). For the Teffs, lower level OCR was found in ITP group compared to NC group (70.58 ± 8.65 vs 89.25 ± 1.37, p=0.0171), Figure 5 
Discussion
ITP is known as an autoimmune disease with decreased Treg cells at its onset. Our previous study has indicated that the balance of Th17/Treg is skewed towards Th17 cells, and Th17/Treg ratio might be associated with the clinical diversity of ITP patients at disease onset [11] . The current study found that the expression levels of IRF4 gene and protein of Treg cells in patients with ITP were lower than that of healthy volunteers. The RNA interference targeting IRF4 genes in Treg cells can weaken Treg cells' inhibition of Th17 cells. Furthermore, IRF4-deficient Treg cells showed compromised immunosuppressive function and impaired suppressive activity in ITP patients. IL-10 is a vital cytokine in immune regulation. It has been shown that Treg cells from IL-10-/-mice lose the ability to inhibit Th17 cells [41] . Such that Treg cells' inhibition function to Th17 cells depends on IL-10 in mice [27] . IL-10 secretion of Tregs was found to be decreased in ITP patients [11, 22] . Insufficient secretion of IL-10 causes impairment of inhibitory capability of Tregs against Teffs in newly diagnosed ITP patients [22] .
Although not all but 5 samples for each group were examined due to the sparse of the blood specimens, the expression level of IRF4mRNA and IRF4 protein of Treg cells in ITP patients did show to be lower than that of healthy volunteers, indicating that the immunosuppressive function of IRF4-deficient Treg cells was impaired in ITP setting. To IRF4 protein, the differences in protein images were not obvious, but statistically significant. Several studies have shown that IRF4 is a main regulator connecting with the differentiation and function of Treg and Th17 cells [42] [43] [44] [45] [46] . The suppressive activity of Treg cells in ITP patients was also found to be impaired [4] . Evidence showed that the expression of the transcription factor Blimp-1 defined a population of Treg cells that localized mainly to mucosal sites and produced IL-10. The transcription factor IRF4 was indispensable for Blimp-1 expression and for the differentiation of Treg cells [47, 48] . Chromatin immunoprecipitation followed by qPCR analysis (ChIP-qPCR) is a widely used technique to study gene expression. In the current study, the target gene IL-10 of IRF4 on CD4 + CD25 hi Foxp3 + Treg cells was studied. The results showed that the intensity of IRF4 binding to IL-10 DNA on Tregs was higher in patients with ITP than that of normal controls and CD4 + CD25 − Teffs. Conversely, the intensity of IRF4 binding to IL-10 DNA on CD4 + CD25 − Teffs was lower than normal control group. No significant difference was found between Tregs and Teffs in healthy volunteers. Our data also showed that the secretion of IL-10 of Treg cells in ITP patients was lower than that of healthy controls. In addition, abnormal expression of interleukin regulatory factor 4 gene and abnormal metabolism in Treg cells were detected in ITP patients. These data suggested that IL-10 secretion of Tregs was damaged in ITP patients, although there is enhanced binding force of IRF4 with IL-10 gene which should be compensatory at the onset of the disease. [49] [50] [51] [52] , plays vital role for T cells differentiation [13, 15, 46, 53] . Our finding suggested that the immunosuppressive function of IRF4-deficient Treg cells was compromised in ITP patients. Consequently the function of Treg cells which is determined by dysfunctional IRF4 regulated IL-10 was also impaired.
The increased glycolysis and decreased oxidative phosphorylation of Teff cells were detected in ITP patients, which indicated that Teff cells in ITP patients were overactivated. It has been shown that IRF4 controls the expression of proteins involved in central metabolic pathways such as glucose uptake, glycolysis, and oxidative phosphorylation and thereby promotes changes in cell metabolism necessary for T cell proliferation and effector functions [54] . Teff cells are dependent on the glucose transporter Glut1 and aerobic glycolysis for proliferation and inflammatory functions, as inhibition of glycolysis or deletion of Glut1 impairs Teff cell function in vivo [35, 36] . Due to the requirement of Seahorse testing technology, the specimens obtained from ITP patients cannot match the requirement for test of OCR and ECAR after IRF4 silencing. Recently, there is study showed that the mTOR-IRF4 may influence the function and activation of peripheral Treg cells [55] . And our data also suggested that there is a link between IRF4 and the metabolism of Treg cells. Treg cell function was impaired, and IL-10 secretion disorder might be related to T cell energy metabolism, which is worthy of further study. [31] . The expression of Foxp3 of Tregs results in decreased glucose uptake, glycolysis, and lactate production [56] .
The increased glycolysis and high ratio of OCR/ECAR of Tregs were found in ITP patients. IL-17 within the Th17 cells was increased; however there was no change of the expression of extracellular IL-17 cytokines after IRF4 gene silencing. The intensity of IRF4 binding to IL-10 DNA on Tregs was increased in ITP patients. The dysfunction of IL-10 secretion of Tregs resulted in inadequate peripheral IL-10 cytokines. These results highly suggested that the immune function of Treg cells in ITP patients could be related to the changes of cell metabolism as abnormal metabolism of Treg and Teff cells in ITP patients were detected. Treg cells are known to have high amounts of IRF4 that depends on Foxp3 expression. The abnormal expression of Foxp3 could result in IRF4 missing, resulting in unable to start the transcription of downstream gene and compromise the immunosuppressive function of Treg cells in patients with autoimmune diseases [18] .
In present study, the abnormal metabolism of Tregs and inadequate secretion of IL-10 seemed to be caused by dysfunction of IRF4 in patients with ITP. The activation of Teff cells was results of abnormal cell metabolism. Taken together, the abnormal secretion of IL-10 and IL-17 was related to the abnormal metabolism of T cells. Further study is needed to validate this mechanism. 
Conclusion
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